Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
AEVR’s executive director on #SeeWhatMatters and safeguarding the National Eye Institute
#SeeWhatMatters is a national advocacy campaign to raise awareness about the importance of federally funded vision research and to protect the independence of the National Eye Institute amid proposed structural changes to the NIH. (Image courtesy of #SeeWhatMatters) The Alliance…
UK MHRA approves phase 2a study for ANXV for diabetic retinopathy
(Image credit: AdobeStock/Janis Smits) UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of a clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye disease diabetic retinopathy (DR). Patients with newly…
Opthea parts with CEO, lays off over 80% of company
(Image Credit: AdobeStock/Andrii Yalanskyi) Opthea has released a corporate update following its settlement of the Development Funding Agreement (“DFA”) with the 2 investors under the DFA.1 The company previously provided an update in April 20252 stating its intention to lay…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…
Study establishes reference data set for geographic atrophy lesion progression
(Image Credit: AdobeStock/tadamichi) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science &…
An eye on how patients perceive their retinal diseases
(Image credit: ©De Visu/AdobeStock) A recent study identified a large disconnect between patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) who are treated with intravitreal injections. The survey results highlighted the significant treatment burden experienced by…
First time results of VOY-101 for geographic atrophy
Omer Trivizki, MD, MBA, at the 2025 ASRS meeting Omer Trivizki, MD, MBA, Deputy Chair working in Tel Aviv Medical Center presented, “First time results of VOY-101, a novel, complement-modulating gene therapy for geographic atrophy.” This presentation was given at…
First patients dosed in JC02-88 study
(Image credit: ©Alernon77/AdobeStock) jCyte recently announced the dosing of the first patients enrolled in the JC02-88 study for the evaluation of famzeretcel (jCell; jCyte) for the treatment of retinitis pigmentosa (RP).1 Famzeretcel consists of allogeneic retinal progenitor cells (RPCs) administered…
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
Boehringer Ingelheim and Palatin Technologies enter into a global research collaboration and licensing agreement
(Image Credit: AdobeStock/Vittaya_25) Boehringer Ingelheim and Palatin Technologies have entered into a global research collaboration and licensing agreement to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases. Under the terms of the agreement, Palatin will receive…